RxDoctor Payments Data

Robert Conroy, DO

Sleep Medicine · Dartmouth, MANPI 1528062858

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Pfizer accounts for 77.0% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $335, 2.7 times the $125 reported in 2019. That places this record below the midpoint for sleep medicine clinicians in MA, where the typical reported total is $559.

$613in general payments, 2019–2025

Across 36 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$471
  • Mylan Specialty L.p.$125
  • Alkermes, Inc.$16

What the payments were for

  • Food & beverage$613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer34$471
Mylan Specialty L.p.1$125
Alkermes, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$613 in reported general payments places this provider in the 50th percentile of 51 sleep medicine providers in Massachusetts.

See all sleep medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$161,864
Medicare patients
540
Services billed
4,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate19$124,338
Austedo XrDeutetrabenazine11$89,158
RytaryCarbidopa/Levodopa26$40,870
LamictalLamotrigine28$31,823
Carbamazepine ErCarbamazepine78$9,310
Levetiracetam305$5,933
Rivastigmine23$5,096
Carbidopa-LevodopaCarbidopa/Levodopa125$5,053
AmantadineAmantadine Hcl84$4,150
Propranolol Hcl ErPropranolol Hcl58$4,129
Mirtazapine218$3,616
Gabapentin318$3,408
Memantine Hcl86$3,401
Carbamazepine53$3,342
Duloxetine Hcl69$2,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerDilantin$471$2,72011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 51 sleep medicine providers in Massachusetts.

Other sleep medicine in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →